Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis
Conditions
Interventions
ALX-101 Gel Vehicle
ALX-101 Gel 5%
Locations
22
United States
Ralexar Investigational Site 10
Beverly Hills, California, United States
Ralexar Investigational Site 5
Los Angeles, California, United States
Ralexar Investigational Site 3
Aventura, Florida, United States
Ralexar Investigational Site 2
Jacksonville, Florida, United States
Ralexar Investigational Site 22
Miami, Florida, United States
Ralexar Investigational Site 18
Pinellas Park, Florida, United States
Start Date
March 8, 2019
Primary Completion Date
January 1, 2020
Completion Date
January 1, 2020
Last Updated
November 5, 2019
NCT06004986
NCT06850311
NCT06454942
NCT05704205
NCT06469385
NCT04773587
Lead Sponsor
Ralexar Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions